Stocks

Fulcrum Therapeutics FULC

Health care sectorNasdaq

What to see in Fulcrum Therapeutics now

Is Wall Street adding or cutting?−14

155 13F filers hold it · −14 against the quarter before · shares held +19.6%

Holdings of 06/30
Who bought more than 5%?0.0%

Ra Capital Management holds 0% · −9.9pp on the report before

Filed 08/14
Is stock about to come to market?$54.4K

$54.4K of planned sales filed in 30 days · under 0.1% of the units outstanding

Filed 09/02

Company

Exchange
Nasdaq
Industry
Pharmaceutical Preparations
Headquarters
Cambridge, Massachusetts
Fiscal year end
12/31
Next earnings
07/01, estimated
  • 155 13F filers hold it · −14 against the quarter before · shares held +19.6%Holdings of 06/30
  • Ra Capital Management holds 0% · −9.9pp on the report beforeFiled 08/14

Funds

13F filers: 155 · −14 since the quarter before · 06/30 holdings

Famous funds that held Fulcrum Therapeutics in their latest 13F report.

FundValueSince the quarter before
Mirae Asset Global ETFS HoldingsFulcrum Therapeutics FULC · 06/30 holdings$100KNo quarter before
Mirae Asset Global InvestmentsFulcrum Therapeutics FULC · 06/30 holdings$10.9KTrimmed −14.2%
All tracked funds

5% stakes

Holder
Ra Capital Management08/140%0 sh−9.9pp
Nantahala Capital Management08/148.22%5,475,040 sh+3.6pp
Montanova Capital08/145.5%3,680,921 sh−3.9pp
TCG Crossover GP II08/140%0 sh−7.9pp
Bank of America08/036.7%4,468,123 shFirst report
BlackRock07/287.2%4,802,880 sh+1.2pp
BlackRock Portfolio Management07/176%4,021,379 shFirst report
Tang Capital Management07/1510.4%6,913,329 sh+2.2pp
EcoR1 Capital06/259%6,000,000 sh+0.0pp
EcoR1 Capital06/259%6,000,000 shFirst report
Tang Capital Management06/108.2%5,451,800 shFirst report
Ra Capital Management02/179.9%6,649,973 sh−1.3pp
Adage Capital Management25/11/134.5%2,432,000 sh−4.0pp
BlackRock25/10/176%3,270,322 sh−1.5pp
Adage Capital Management25/08/128.5%4,589,000 sh+2.9pp
Suvretta Capital Management25/05/029.4%5,067,394 sh+3.1pp
Adage Capital Management25/02/125.56%3,000,000 shFirst report
Suvretta Capital Management25/01/066.3%3,404,612 shFirst report
All 5% stake reports on Fulcrum Therapeutics

26-week trading